Piper Sandler set a $15.00 target price on NextCure (NASDAQ:NXTC - Free Report) in a research report released on Tuesday, MarketBeat Ratings reports. The firm currently has an overweight rating on the stock.
A number of other equities research analysts have also recently issued reports on the stock. LADENBURG THALM/SH SH upgraded shares of NextCure to a "hold" rating in a report on Tuesday, July 8th. HC Wainwright reaffirmed a "buy" rating and set a $36.00 price objective on shares of NextCure in a research report on Tuesday, July 1st.
Check Out Our Latest Research Report on NextCure
NextCure Price Performance
NASDAQ:NXTC traded down $0.14 during trading hours on Tuesday, reaching $4.99. The company's stock had a trading volume of 29,253 shares, compared to its average volume of 11,548. The company has a market cap of $13.37 million, a price-to-earnings ratio of -0.24 and a beta of 1.06. NextCure has a one year low of $2.69 and a one year high of $21.48. The business's 50-day moving average is $5.68 and its 200-day moving average is $6.89.
NextCure (NASDAQ:NXTC - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($4.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.80) by $0.12. On average, sell-side analysts predict that NextCure will post -1.87 EPS for the current fiscal year.
Hedge Funds Weigh In On NextCure
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Pfizer Inc boosted its stake in NextCure by 29.7% in the first quarter. Pfizer Inc now owns 1,891,763 shares of the company's stock valued at $909,000 after acquiring an additional 433,213 shares during the last quarter. Tang Capital Management LLC raised its holdings in NextCure by 7.3% in the fourth quarter. Tang Capital Management LLC now owns 700,000 shares of the company's stock worth $540,000 after purchasing an additional 47,614 shares during the period. Renaissance Technologies LLC raised its holdings in NextCure by 27.9% in the fourth quarter. Renaissance Technologies LLC now owns 519,300 shares of the company's stock worth $400,000 after purchasing an additional 113,300 shares during the period. Finally, Citadel Advisors LLC raised its holdings in NextCure by 40.6% in the fourth quarter. Citadel Advisors LLC now owns 78,678 shares of the company's stock worth $61,000 after purchasing an additional 22,724 shares during the period. 42.65% of the stock is owned by institutional investors.
About NextCure
(
Get Free Report)
NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.
Read More
Before you consider NextCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NextCure wasn't on the list.
While NextCure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
